Delivering New Treatment Options for Recurrent Gynecologic Cancers
NCT03968406 · RecruitingThis trial looks at how well talazoparib works with radiation therapy for treating gynecologic cancers that have come back after treatment. Talazoparib may help stop the growth of cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The goal is to find the best dose of talazoparib and see how safe this combination is for patients.
Locations and contact
This trial is running at 2 locations in the United States. All of them are currently recruiting.
United States2 locations · 2 recruiting
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, MarylandRecruiting
- M D Anderson Cancer CenterHouston, TexasRecruiting
Who can join
This study is for adults aged 18 and older, including men and women. Participants need to have certain types of recurrent gynecologic cancers, like ovarian or cervical cancer. They should be healthy enough to participate and not need immediate chemotherapy. The trial team will check if each person can join based on specific health criteria.
What happens during the trial
Everyone in the trial will receive talazoparib and radiation therapy. Talazoparib is taken by mouth once a day for 8 weeks, while radiation therapy is given 5 days a week for up to 7 weeks. The trial is designed to see how well these treatments work together.
The trial team
The trial is sponsored by M.D. Anderson Cancer Center. Dr. Lilie L Lin is the principal investigator leading the study, with help from the National Cancer Institute.
Important dates
The trial started on September 26, 2019, and is expected to finish by October 1, 2027. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT03968406. It is a Phase 1 trial, meaning it is looking for the best dose of the treatment and how safe it is. The trial is FDA-regulated and aims to include about 24 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →